Yousif Capital Management LLC Lowers Stock Position in Glaukos Co. (NYSE:GKOS)

Yousif Capital Management LLC decreased its position in Glaukos Co. (NYSE:GKOS) by 2.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 20,777 shares of the medical instruments supplier’s stock after selling 481 shares during the quarter. Yousif Capital Management LLC’s holdings in Glaukos were worth $2,045,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in the company. Harbor Capital Advisors Inc. increased its position in shares of Glaukos by 59.5% during the 1st quarter. Harbor Capital Advisors Inc. now owns 39,132 shares of the medical instruments supplier’s stock valued at $3,851,000 after purchasing an additional 14,593 shares during the last quarter. Whipplewood Advisors LLC increased its position in Glaukos by 3,957.1% during the 1st quarter. Whipplewood Advisors LLC now owns 284 shares of the medical instruments supplier’s stock valued at $28,000 after buying an additional 277 shares in the last quarter. LVW Advisors LLC increased its holdings in shares of Glaukos by 5.9% in the first quarter. LVW Advisors LLC now owns 2,408 shares of the medical instruments supplier’s stock valued at $237,000 after purchasing an additional 135 shares during the period. GAMMA Investing LLC increased its holdings in shares of Glaukos by 5,912.8% in the first quarter. GAMMA Investing LLC now owns 133,064 shares of the medical instruments supplier’s stock valued at $13,096,000 after purchasing an additional 130,851 shares during the period. Finally, Versant Capital Management Inc grew its holdings in Glaukos by 583.9% during the first quarter. Versant Capital Management Inc now owns 383 shares of the medical instruments supplier’s stock worth $38,000 after acquiring an additional 327 shares during the period. Institutional investors own 99.04% of the company’s stock.

Glaukos Price Performance

Shares of NYSE:GKOS opened at $97.69 on Monday. The business’s 50 day simple moving average is $92.76 and its 200-day simple moving average is $119.66. The firm has a market capitalization of $5.58 billion, a price-to-earnings ratio of -34.04 and a beta of 0.80. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. Glaukos Co. has a 12 month low of $77.10 and a 12 month high of $163.71.

Glaukos (NYSE:GKOS) last posted its earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.11. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The firm had revenue of $106.66 million for the quarter, compared to analyst estimates of $102.78 million. During the same quarter in the prior year, the company earned ($0.70) EPS. Glaukos’s revenue was up 24.6% on a year-over-year basis. As a group, equities analysts forecast that Glaukos Co. will post -1.08 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Glaukos news, CFO Alex R. Thurman sold 1,520 shares of the firm’s stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total value of $162,396.80. Following the transaction, the chief financial officer now directly owns 53,431 shares of the company’s stock, valued at $5,708,568.04. This trade represents a 2.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 5.80% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on GKOS. Needham & Company LLC lowered their price target on Glaukos from $176.00 to $115.00 and set a “buy” rating on the stock in a research report on Thursday, May 1st. Truist Financial reiterated a “buy” rating and issued a $135.00 target price (down from $140.00) on shares of Glaukos in a report on Thursday, May 1st. Stephens decreased their price target on Glaukos from $140.00 to $115.00 and set an “overweight” rating for the company in a report on Friday, May 2nd. Morgan Stanley reduced their target price on Glaukos from $110.00 to $72.00 and set an “underweight” rating for the company in a report on Tuesday, May 6th. Finally, Mizuho dropped their price target on Glaukos from $200.00 to $175.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 16th. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $134.67.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.